Page 2554 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 157 Hematologic Manifestations of HIV/AIDS 2277

REFERENCES in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr
37(2):1245–1252, 2004.
1. Shen H, Cheng T, Preffer FI, et al: Intrinsic human immunodeficiency 15. Buskin SE, Sullivan PS: Anemia and its treatments and outcome in
virus type 1 resistance of hematopoietic stem cells despite coreceptor persons infected with human immunodeficiency virus. Transfusion
expression. J Virol 73(1):728–737, 1999. 44(6):826–832, 2004.
2. Bahner I, Kearns K, Coutinho S, et al: Infection of human marrow 16. de Mayolo JA, Temple JD: Pure red cell aplasia due to parvovirus B19
immunodeficiency virus-1 (HIV-1) is both required and sufficient for infection in a man with HIV infection. South Med J 83(12):1480–1481,
HIV-1 inducted hematopoietic suppression in vitro: demonstration by 1990.
gene modification of primary human stroma. Blood 90(5):1787–1798, 17. Chen M, Chien-Ching H, Fang C, et al: Reconstituted immunity
1997. against persistant parvovirus B19 infection in a patient with acquired
3. Gradstein S, Hahn T, Barak Y, et al: In vitro effects of recombinant immunodeficiency syndrome after highly active antiretroviral therapy.
TNF-alfa binding protein (rTBP-1) on hematopoiesis of HIV-infected Clin Infect Dis 32(9):1361–1365, 2001.
patients. J Acquir Immune Defic Syndr 26(2):111–117, 2001. 18. Levine AM, Karim R, Mack W, et al: Neutropenia in human immuno-
4. Huang SS, Barbour JD, Deeks SG, et al: Reversal of immunodeficiency deficiency virus infection. Arch Intern Med 166(4):405–410, 2006.
virus type 1-associated hematosupression by effective antiretroviral 19. Moore DAJ, Benepal T, Portsmouth S, et al: Etiology and natural history
therapy. Clin Infect Dis 30(3):504–510, 2000. of neutropenia in human immunodeficiency virus disease: a prospective
5. Parker NG, Notermans DW, de Boer RG, et al: Biphasic kinetics of study. Clin Infect Dis 32:469–475, 2001.
peripheral blood T cells after triple combination therapy in HIV-1 20. Dubreuil-Lemaire ML, Gori A, Vittecog D, et al: Lenograstim for the
infection: a composite of redistribution and proliferation. Nat Med treatment of neutropenia in patients receiving ganciclovir for cyto-
4(2):208–214, 1998. megalovirus infection: a randomized placebo-controlled trial in AIDS
6. Zhao X, Sun NC, Witt MD, et al: Changing pattern of AIDS: a bone patients. Eur J Haematol 65(5):337–343, 2000.
marrow study. Am J Clin Pathol 121(3):393–401, 2004. 21. Battaieb A, Fromont P, Louache F, et al: Presence of cross-reactive anti-
7. Coyle TE: Hematological complications of human immunodeficiency body between HIV and platelet glycoproteins in HIV-related immune
virus infection and the acquired immunodeficiency syndrome. Med Clin thrombocytopenic purpura. Blood 80(1):162–169, 1992.
North Am 81(2):449–470, 1997. 22. Caso JAA, Mingo CS, Tena JG: Effect of highly active antiretroviral
8. Sullivan PS, Hanson DL, Chu SY, et al: Epidemiology of anemia in therapy on thrombocytopenia in patients with HIV infection. N Engl J
human immunodeficiency virus (HIV)-infected persons: results from the Med 341(16):1239–1240, 1999.
MutistateAdult and Adolescent Spectrum of HIV Disease Surveillance 23. Bussel JB, Haimi JS: Isolated thrombocytopenia in patients infected
Project. Blood 91(1):301–308, 1998. with HIV: treatment with intravenous immunoglobulin. Am J Hematol
9. Abrams DI, Steinhart C, Frascino R: Epoetin alfa therapy for anaemia 28(2):79–84, 1988.
in HIV-infected patients: impact on quality of life. Int J STD AIDS 24. Scaradavou A, Woo B, Woloski BM, et al: Intravenous anti-D treatment
11(10):659–665, 2000. of immune thrombocytopenic purpura: experience in 272 patients. Blood
10. Moore RD, Forney D: Anemia in HIV infected patients receiving highly 89(8):2689–2700, 1997.
active antiretroviral therapy. J Acquir Immune Defic Syndr 29(1):54–57, 25. Leaf AN, Laubenstein LJ, Raphael B, et al: Thrombotic thrombocy-
2002. topenic purpura associated with human immunodeficiency virus type
11. Lundgren JD, Mocroft A, Gatell JM, et al: A clinically prognostic scoring 1(HIV-1) infection. Ann Intern Med 109(3):194–197, 1988.
system for patients receiving highly active antiretroviral therapy: results 26. Novitzky N, Thomson J, Abrahams L, et al: Thrombotic thrombocyto-
from the EuroSIDA Study. J Infect Dis 185(2):178–187, 2002. penic purpura in patients with retroviral infection is highly responsive
12. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of to plasma infusion therapy. Br J Haematol 128(3):373–379, 2005.
one-weekly dosing of epoetin alpha in chemotherapy patients: improve- 27. Sullivan PS, Dworkin MS, Jones JL, et al: Epidemiology of thrombosis
ments in hemoglobin and quality of life are similar to three-times-weekly in HIV-infected individuals. AIDS 14(3):321–324, 2000.
dosing. J Clin Oncol 19(11):2875–2882, 2001. 28. Levine AM, Vigen C, Gravink J, et al: Progressive prothrombotic state
13. Isgrò I, Auiti A, Mezzaroma I, et al: HIV type I protease inhibitors in women with advancing HIV disease. J Acquir Immune Defic Syndr
enhance bone marrow progenitor cell activity in normal subjects and 42(5):572–577, 2006.
HIV type 1-infected patients. AIDS Res Hum Retroviruses 21(1):51–57, 29. George S, Swindells S, Knudson R, et al: Unexplained thrombosis in
2005. HIV-infected patients receiving protease inhibitors: report of seven cases.
14. Berhane K, Karim R, Cohen MH, et al: Impact of highly active antiret- Am J Med 107(6):624–626, 1999.
roviral therapy on anemia and relationship between anemia and survival